CTNM
NASDAQContineum Therapeutics Inc.
News25/Ratings5
News · 26 weeks49-57%
2026-03-012026-08-23
Mix2490d
- Insider14(58%)
- Other6(25%)
- SEC Filings4(17%)
Latest news
25 items- PRContineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum’s website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
- INSIDERCEO and President Stengone Carmine N. sold $40,029 worth of shares (2,500 units at $16.01) as part of a pre-agreed trading plan and exercised 2,500 shares at a strike of $1.01 (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- SECSEC Form 10-Q filed by Contineum Therapeutics Inc.10-Q - Contineum Therapeutics, Inc. (0001855175) (Filer)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- PRContineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development MilestonesContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and affirmed its key clinical development milestones. "We continue to expand our footprint for PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients with idiopathic pulmonary fibrosis (IPF), with more than 55 sites now online in eight countries to enable a steady pace of enrollment," said Carmine Stengone, CEO, Contineum Therapeutics. "In addition, Johnson & Johnson complet
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- INSIDERChief Scientific Officer Lorrain Daniel S. exercised 1,040 shares at a strike of $1.01 and sold $16,640 worth of shares (1,040 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERCEO and President Stengone Carmine N. exercised 2,500 shares at a strike of $1.01 and sold $40,000 worth of shares (2,500 units at $16.00) as part of a pre-agreed trading plan (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERChief Scientific Officer Lorrain Daniel S. exercised 33,009 shares at a strike of $1.01 and sold $594,578 worth of shares (37,179 units at $15.99) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 135,202 units (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERCMO & Head of Development Watkins Tim exercised 10,833 shares at a strike of $4.50 and sold $173,590 worth of shares (10,833 units at $16.02) as part of a pre-agreed trading plan (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERCEO and President Stengone Carmine N. exercised 10,000 shares at a strike of $1.07 and sold $160,080 worth of shares (10,000 units at $16.01) as part of a pre-agreed trading plan (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry- Manuscript describes the discovery of LPAR1 antagonist PIPE-791, now in a Phase 2 clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF)- Blocking LPAR1 inhibits key steps in the fibrosis pathway with potential targets in several therapeutic indicationsContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, "Discovery of PIPE-791, a Potent and
- INSIDERSEC Form 4 filed by Director Miralles Gines Diego4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Lyons-Williams Lori4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Ware Olivia C4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Schimmelpennink Evert B.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Ignelzi Troy A.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Brady Todd R.4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- INSIDERSEC Form 4 filed by Director Boyce Sarah4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- SECContineum Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Contineum Therapeutics, Inc. (0001855175) (Filer)
- INSIDERChief Scientific Officer Lorrain Daniel S. sold $54,862 worth of shares (4,170 units at $13.16) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 139,372 units (SEC Form 4)4 - Contineum Therapeutics, Inc. (0001855175) (Issuer)
- PRContineum Therapeutics to Present at the 2026 Goldman Sachs Global Healthcare ConferenceContineum Therapeutics, Inc. (NASDAQ:CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that management is scheduled to present at the 2026 Goldman Sachs Global Healthcare Conference on Tuesday, June 9th at 1:20 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of Contineum's website. A webcast replay will also be available. About Contineum Therapeutics Contineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Contineum Therapeutics Inc.SCHEDULE 13G/A - Contineum Therapeutics, Inc. (0001855175) (Subject)
CTNM FAQ
6 questionsWhere does CTNM stock trade?
Contineum Therapeutics Inc. (CTNM) is listed on NASDAQ.What sector and industry is CTNM in?
Contineum Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Contineum Therapeutics Inc. go public?
Contineum Therapeutics Inc. (CTNM) completed its IPO in 2024.What are analysts saying about CTNM?
Contineum Therapeutics Inc. has had 5 recent analyst actions on file. The most recent action was from Morgan Stanley: Equal-Weight with a $1400.00 price target on 2026-01-08. Recent price targets range from $1400.00 to $3200.00.What companies are similar to CTNM?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CTNM side-by-side with any of them on Quantisnow.How can I track CTNM on Quantisnow?
Quantisnow aggregates Contineum Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CTNM to receive live email and push alerts on every new disclosure.